SARS-CoV-2 research solutions

Ancell Technology Inc. 9F, No.74, Songde Rd., Xinyi Dist., Taipei City 110, Taiwan

The SARS-CoV-2 pandemic is transitioning into a new phase. Besides long-term effects after infection, researchers are monitoring emerging SARS-CoV-2 variants and their impact on the antiviral immune response as well as vaccine performance.Miltenyi Biotec stands committed to support these studies. We continuously develop new products adjusted to emerging SARS-CoV-2 variants. Furthermore, we provide tools and protocols that are ideally suited for working with infectious material.B cellsSARS-CoV-2 specific B cells and antibodiesT cellsSolutions for stimulation, enrichment, and analysis of rare virus-specific T cellsNK cellsFast isolation and subsequent expansion of NK cellsMyeloid cellsEnrichment and culture of myeloid cells for immunogenicity assays and study of inflammationMACS® Cell Culture and StimulationSARS-CoV-2 PepTivator® Peptide Pools – Virus-specific T cell stimulation – APC loadingMACS® Cell Culture and StimulationAntigens for SARS-CoV-2 research – Investigate virus-specific B cells and antibodiesMACS AntibodiesRecombinant antibodies for immunophenotyping during COVID-19 researchExosomesExosome research solutions for infectious diseases https://www.ancell-bio.com.tw/en/hot_396599.html SARS-CoV-2 research solutions: Helping researchers in their work on viral threats 2025-04-07 2026-04-07

Ancell Technology Inc. 9F, No.74, Songde Rd., Xinyi Dist., Taipei City 110, Taiwan https://www.ancell-bio.com.tw/en/hot_396599.html

Ancell Technology Inc. 9F, No.74, Songde Rd., Xinyi Dist., Taipei City 110, Taiwan https://www.ancell-bio.com.tw/en/hot_396599.html

https://schema.org/EventMovedOnline https://schema.org/OfflineEventAttendanceMode

2025-04-07 http://schema.org/InStock TWD 0 https://www.ancell-bio.com.tw/en/hot_396599.html

Ancell Technology Inc.

Home NEWS COVID-19 research SARS-CoV-2 research solutions: Helping researchers in their work on viral threats

Links：https://www.miltenyibiotec.com/CN-en/lp/assisting-researcher ...

The SARS-CoV-2 pandemic is transitioning into a new phase. Besides long-term effects after infection, researchers are monitoring emerging SARS-CoV-2 variants and their impact on the antiviral immune response as well as vaccine performance.

Miltenyi Biotec stands committed to support these studies. We continuously develop new products adjusted to emerging SARS-CoV-2 variants. Furthermore, we provide tools and protocols that are ideally suited for working with infectious material.

B cells
SARS-CoV-2 specific B cells and antibodies
T cells
Solutions for stimulation, enrichment, and analysis of rare virus-specific T cells
NK cells
Fast isolation and subsequent expansion of NK cells
Myeloid cells
Enrichment and culture of myeloid cells for immunogenicity assays and study of inflammation
MACS® Cell Culture and Stimulation
SARS-CoV-2 PepTivator® Peptide Pools – Virus-specific T cell stimulation – APC loading
MACS® Cell Culture and Stimulation
Antigens for SARS-CoV-2 research – Investigate virus-specific B cells and antibodies
MACS Antibodies
Recombinant antibodies for immunophenotyping during COVID-19 research
Exosomes
Exosome research solutions for infectious diseases

Back to List Next